Gemma Biotherapeutics, co-founded by James Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director’s Professor at Penn Medicine, raised $34 million in a seed round led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital, with additional backing from Savanne Life Sciences.
The funding will go towards the company’s operational expansion and to help accelerate Gemma Bio’s mission to provide affordable gene therapies to patients with rare diseases. Read more here and here.